Dako has resolved FDA issue
Dako has sorted out the problems which resulted in a warning letter from the FDA to the Danish-based company a few years ago.
BY BENJAMIN WERNER CHRISTENSEN
The Danish-based company Dako, which specializes in cancer diagnostics, has resolved the issues that resulted in a warning letter from the FDA in the fall of 2013, the company, a subsidiary to US-based Agilent Technologies, announces in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Dako CEO to resign
For abonnenter
Medtech company to market novel diagnostic test in US
For abonnenter
Dako-CEO: Important and fast-growing business area
For abonnenter
